Gold
EW4A: Sep. 25 (Fri), 12:00-13:00/ Room A (2F)
A global leader in in vitro diagnostics for over 55 years, bioMérieux has always been driven by a pioneering spirit and unrelenting commitment to improve public health worldwide. The Company is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. It provides diagnostic solutions that improve patient health and ensure consumer safety. bioMérieux develops and produces in vitro diagnostic solutions (systems, reagents, software and services) for private and hospital laboratories, mainly for the diagnosis of infectious diseases. The results obtained from a patient sample (blood, urine, stool, cerebrospinal fluid, saliva, etc.) provide doctors with information to support their decisions.
Quickly identify SARS-CoV-2, along with 21 additional viral and bacterial pathogens that are common cause of respiratory illness. Many respiratory illnesses present with nearly indistinguishable symptoms. The BioFire RP2.1 Panel provides rapid answers on a comprehensive menu of pathogens to give physicians confidence in their treatment decisions.
The BioFire PN Panel identifies 33 clinically relevant targets from sputum (including endotracheal aspirate) and bronchoalveolar lavage (including mini-BAL) samples. For 15 of the bacteria, the BioFire PN Panel provides semi-quantitative results, which may help determine whether an organism is a colonizer or a pathogen.
bioMérieux provides clinical laboratories with comprehensive diagnostic solutions for bacterial screening, infection control and appropriate antimicrobial treatment guidelines. Our high medical value diagnostic tests contribute to AMS with timely detection and diagnosis of medical-related and multi-drug resistant infections.
